NasdaqGS - Nasdaq Real Time Price USD

FibroGen, Inc. (FGEN)

Compare

0.3080

-0.0120

(-3.75%)

At close: October 25 at 4:00 PM EDT

0.3118

+0.00

(+1.23%)

After hours: October 25 at 6:07 PM EDT

FibroGen Inc (FGEN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Shifts

FibroGen Inc (FGEN) reports significant revenue increases and strategic pivots amid challenges in clinical trials and market competition.

GuruFocus.com 16 days ago

FGEN
-3.75%
Duchenne muscular dystrophy: major trials and events to watch in 2023

A possible gene therapy approval and a series of major trials readouts set the stage for a busy year of drug development in Duchenne muscular dystrophy.

Clinical Trials Arena last month

GLDAF

FGEN
-3.75%
FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

SAN FRANCISCO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY. Thane Wettig, Chief Executive Officer of FibroGen, will deliver a company presentation on Tuesday, September 10 at 3:00 PM ET at the Lotte New York Palace Hotel. A live webcast of the presentation will be available here. FibroGen’s managemen

GlobeNewswire last month

FGEN
-3.75%
FibroGen, Inc. (NASDAQ:FGEN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

A week ago, FibroGen, Inc. ( NASDAQ:FGEN ) came out with a strong set of second-quarter numbers that could potentially...

Simply Wall St. 2 months ago

FGEN
-3.75%
FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of 38.46% and 53.46%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

FGEN
-3.75%
FibroGen: Q2 Earnings Snapshot

SAN FRANCISCO (AP) — FibroGen Inc. FGEN) on Tuesday reported a loss of $15.5 million in its second quarter. On a per-share basis, the San Francisco-based company said it had a loss of 16 cents.

Associated Press Finance 2 months ago

FGEN
-3.75%
FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update

Company implementing significant cost reduction plan in the U.S. due to results in late-stage pamrevlumab pancreatic cancer trials, including a reduction of U.S. workforce by approximately 75%Focus R&D investment on FG-3246 and PET46, a first-in-class anti-CD46 antibody-drug conjugate and companion PET imaging agent for metastatic castration-resistant prostate cancer (mCRPC) Presented compelling preliminary data from dose escalation portion of Phase 1b/2 investigator-sponsored study of FG-3246,

GlobeNewswire 2 months ago

FGEN
-3.75%
FibroGen axes 75% of staff after lead cancer therapy fails in Phase III trials

FibroGen’s pancreatic cancer therapy, pamrevlumab, failed to prove its efficacy in two Phase III trials prompting the company to initiate cost-saving measures.

Pharmaceutical Technology 2 months ago

FGEN
-3.75%
Vertex’s pain drug gets speedy FDA review; Keytruda hits a sales milestone

Quarterly sales of Merck’s immunotherapy crested $7 billion for the first time. Elsewhere, Fibrogen is laying off staff and Intellia has a green light to start a new gene editing trial in the U.K.

BioPharma Dive 2 months ago

FGEN
-3.75%
NTLA

BIIB
FibroGen to Report Second Quarter 2024 Financial Results

SAN FRANCISCO, July 30, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce second quarter 2024 financial results on Tuesday, August 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast Toll-free: 1-877-300-8521International investors: 1-412-317-6026Webcast: Click here To access the call, participants

GlobeNewswire 2 months ago

FGEN
-3.75%
FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate Update

Pamrevlumab arm of the Precision PromiseSM study in metastatic pancreatic cancer, sponsored and conducted by the Pancreatic Cancer Action Network (PanCAN), did not meet the primary endpoint of overall survival as determined by the protocol pre-specified Bayesian statistical analysisLAPIS study in locally advanced, unresectable pancreatic cancer, sponsored by FibroGen, did not meet the primary endpoint of overall survival Pamrevlumab was generally safe and well tolerated across both studies, with

GlobeNewswire 2 months ago

FGEN
-3.75%
FibroGen, Inc. (NASDAQ:FGEN) is a favorite amongst institutional investors who own 54%

Key Insights Given the large stake in the stock by institutions, FibroGen's stock price might be vulnerable to their...

Simply Wall St. 2 months ago

FGEN
-3.75%
Favourable Signals For FibroGen: Numerous Insiders Acquired Stock

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...

Simply Wall St. 4 months ago

FGEN
-3.75%
FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024

SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To register, click here. The event will feature Rahul Aggarwal, M.D. (University of California San Francisco), who will discuss the unmet need and evolving treatment landscape for prostate cancer, as well as the clinical development program for FG-3246* (also known as FOR46), a CD46 targeti

GlobeNewswire 4 months ago

FGEN
-3.75%
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO® in patients with select solid tumorsFibroGen to evaluate FG-3175, an anti-c-c motif chemokine receptor 8 (CCR8) mAb, as monotherapy treatment as well as in combination with LIBTAYO® in patients with select solid tumorsBoth FG-3165 and FG-3175 have demonstrated complementary mechanisms of action with PD-1 inhibitors in preclinical studies SAN FRANCISC

GlobeNewswire 4 months ago

FGEN
-3.75%
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

The safety and efficacy of FG-3165 will be evaluated in a Phase 1 trial in select solid tumorsPlan to begin enrollment in 2H 2024 SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) of FG-3165, a galectin-9 (Gal9) targeted monoclonal antibody under development for treatment of solid tumors characterized by high Gal9 levels of expression. “The FDA’s

GlobeNewswire 4 months ago

FGEN
-3.75%
FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference

SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a Fireside Chat at Goldman Sachs 45th Annual Global Healthcare Conference to be held in Miami, Florida on Monday, June 10, 2024, from 10:00-10:35 AM Eastern Time. Company management will also participate in one-on-one meetings with investors during the conference. A live audio webcast of the event will be available to investors and other i

GlobeNewswire 4 months ago

FGEN
-3.75%
7 Penny Biotech Stocks to Triple Your Investment

One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny biotech stocks. Developing therapeutics to cure diseases is a complex business model fraught with the potential to fail at many points. Developmental and regulatory time frames are long, introducing multiple potential points of failure. The capital necessary for research and development is substantial. So on and so forth. The result is that many upstart biotech firm

InvestorPlace 4 months ago

AFMD

LPCN

NVCT
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting

FG-3246 and enzalutamide combination therapy led to a median radiographic progression free survival (rPFS) of 10.2 months in biomarker unselected patientsFG-3246 demonstrated an acceptable safety profile; adverse events consistent with those observed in other antibody drug conjugate therapies with a MMAE payloadRecommended Phase 2 dose of FG-3246 was established at 2.1 mg/kg every 3 weeks in combination with enzalutamide given at the standard dose of 160 mg daily SAN FRANCISCO, May 23, 2024 (GLO

GlobeNewswire 5 months ago

FGEN
-3.75%
FibroGen First Quarter 2024 Earnings: Beats Expectations

FibroGen ( NASDAQ:FGEN ) First Quarter 2024 Results Key Financial Results Revenue: US$55.9m (up 55% from 1Q 2023). Net...

Simply Wall St. 5 months ago

FGEN
-3.75%

Performance Overview

Return	FGEN	S&P 500
YTD	-65.24%	+21.77%
1-Year	-40.54%	+36.74%
3-Year	-97.16%	+27.79%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

FibroGen, Inc. (FGEN)

FibroGen Inc (FGEN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Shifts

Duchenne muscular dystrophy: major trials and events to watch in 2023

FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

FibroGen, Inc. (NASDAQ:FGEN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates

FibroGen: Q2 Earnings Snapshot

FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update

FibroGen axes 75% of staff after lead cancer therapy fails in Phase III trials

Vertex’s pain drug gets speedy FDA review; Keytruda hits a sales milestone

FibroGen to Report Second Quarter 2024 Financial Results

FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate Update

FibroGen, Inc. (NASDAQ:FGEN) is a favorite amongst institutional investors who own 54%

Favourable Signals For FibroGen: Numerous Insiders Acquired Stock

FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference

7 Penny Biotech Stocks to Triple Your Investment

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting

FibroGen First Quarter 2024 Earnings: Beats Expectations

Performance Overview